Back to News
Market Impact: 0.42
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
Source: cnbc.com
Healthcare & BiotechConsumer Demand & RetailCompany Fundamentals
Eli Lilly CEO Dave Ricks said 700,000 new seniors have begun GLP-1 therapies since Medicare started covering obesity drugs in July, with approximately 70% using Lilly medicines. The data signals substantial incremental demand from Medicare beneficiaries and supports Lilly's competitive position in the obesity-drug market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
LLY0.72
More News
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why Novo Nordisk Stock Just Crashed
- Morgan Stanley's top picks list trounced the S&P 500 the last 12 months. Here are the new members
- Smart ring maker Oura, shareholders look to raise up to $2.2 billion in US IPO
- Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
- Oppenheimer reiterates Viking Therapeutic stock rating on maintenance data potential
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search
- Automating Financial Model Updates: A Source-Controlled Workflow